Laura García-Otero1, Marta López, Olga Gómez, Ana Goncé, Mar Bennasar, Josep Maria Martínez, Brenda Valenzuela-Alcaraz, Mérida Rodriguez-López, Marta Sitges, Montserrat Loncà, Bart Bijnens, Fàtima Crispi, Eduard Gratacós. 1. aBCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Deu), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, and Centre for Biomedical Research on Rare Diseases (CIBER-ER) bDepartment of Cardiology, Thorax Clinic Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona cInfectious Diseases Department, Hospital Clinic, Fundació Clínic per a la Recerca Biomèdica (FCRB), University of Barcelona dICREA, Universitat Pompeu Fabra, Barcelona, Spain.
Abstract
OBJECTIVE: To evaluate the cardiac structure and function of the fetuses of pregnant women with HIV infection on combined antiretroviral treatment (cART) and the HIV-related and nonrelated determinants of abnormal findings. DESIGN: A prospective cohort study including 42-noninfected fetuses from HIV pregnant women on cART and 84 fetuses from non-HIV-infected women. METHODS: Fetal echocardiography was performed at 26-32 weeks of pregnancy to assess cardiac structure and function. The impact of maternal and perinatal factors on fetal cardiac remodelling was evaluated by multivariate regression analysis. RESULTS: Fetuses from HIV pregnant women on cART presented larger hearts and pericardial effusion together with thicker myocardial septal walls (mean 3.56 mm (SD 0.88) vs non-HIV mean 2.75 mm (SD 0.77); P = 0.002) and smaller left ventricular cavities (10.81 mm (SD 2.28) vs 12.3 mm (SD 2.54); P = 0.033). Fetuses from HIV women also presented signs of systolic (mitral systolic annular peak velocity 5.85 cm/s (SD 0.77) vs non-HIV 6.25 cm/s (SD 0.97); P = 0.007) and diastolic (isovolumic relaxation time 52 ms (SD 8.91) vs non-HIV 45 ms (SD 7.98); P < 0.001) dysfunction. In the multivariate analysis, maternal treatment with zidovudine was the only factor significantly associated with fetal cardiac changes (P = 0.014). CONCLUSION: Fetuses from HIV-infected mothers on cART have cardiac remodelling and dysfunction, which might explain the cardiovascular changes described in childhood. Fetal cardiac remodelling was essentially associated with maternal treatment with zidovudine which challenges its use during pregnancy.
OBJECTIVE: To evaluate the cardiac structure and function of the fetuses of pregnant women with HIV infection on combined antiretroviral treatment (cART) and the HIV-related and nonrelated determinants of abnormal findings. DESIGN: A prospective cohort study including 42-noninfected fetuses from HIV pregnant women on cART and 84 fetuses from non-HIV-infectedwomen. METHODS: Fetal echocardiography was performed at 26-32 weeks of pregnancy to assess cardiac structure and function. The impact of maternal and perinatal factors on fetal cardiac remodelling was evaluated by multivariate regression analysis. RESULTS: Fetuses from HIV pregnant women on cART presented larger hearts and pericardial effusion together with thicker myocardial septal walls (mean 3.56 mm (SD 0.88) vs non-HIV mean 2.75 mm (SD 0.77); P = 0.002) and smaller left ventricular cavities (10.81 mm (SD 2.28) vs 12.3 mm (SD 2.54); P = 0.033). Fetuses from HIV women also presented signs of systolic (mitral systolic annular peak velocity 5.85 cm/s (SD 0.77) vs non-HIV 6.25 cm/s (SD 0.97); P = 0.007) and diastolic (isovolumic relaxation time 52 ms (SD 8.91) vs non-HIV 45 ms (SD 7.98); P < 0.001) dysfunction. In the multivariate analysis, maternal treatment with zidovudine was the only factor significantly associated with fetal cardiac changes (P = 0.014). CONCLUSION: Fetuses from HIV-infected mothers on cART have cardiac remodelling and dysfunction, which might explain the cardiovascular changes described in childhood. Fetal cardiac remodelling was essentially associated with maternal treatment with zidovudine which challenges its use during pregnancy.
Authors: Paige L Williams; Katharine Correia; Brad Karalius; Russell B Van Dyke; James D Wilkinson; William T Shearer; Steven D Colan; Steven E Lipshultz Journal: AIDS Date: 2018-10-23 Impact factor: 4.177
Authors: Steven E Lipshultz; Nao Sasaki; Bruce Thompson; Benjamin W Eidem; Irene Cheng; Steven D Colan; Sharon E O'Brien; Shahnawaz Amdani; William T Shearer; Endel John Orav; Tracie L Miller; James D Wilkinson Journal: AIDS Date: 2020-03-15 Impact factor: 4.177
Authors: Jordan G Schnoll; Brian Temsamrit; Daniel Zhang; Hongjun Song; Guo-Li Ming; Kimberly M Christian Journal: J Neuroimmune Pharmacol Date: 2019-09-11 Impact factor: 4.147
Authors: Laura García-Otero; Marta López; Mariona Guitart-Mampel; Constanza Morén; Anna Goncé; Carol Esteve; Laura Salazar; Olga Gómez; Josep María Martínez; Berta Torres; Sergi César; Glòria Garrabou; Fàtima Crispi; Eduard Gratacós Journal: PLoS One Date: 2019-03-04 Impact factor: 3.240